MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM

Hong-Yun Liu¹, Yu-Ying Zhang¹, Bao-Lian Zhu², Fu-Zhong Feng¹, Hai-Tang Zhang¹, Hua Yan¹ and Bin Zhou³*

Abstract

Objective: To investigate whether miR-203a-3p can regulate the biological behaviors of ovarian cancer cells by targeting ATM to affect the Akt/GSK-3β/Snail signaling pathway.

Methods: The expression levels of miR-203a-3p and ATM were detected by qRT-PCR, immunohistochemical staining and Western blotting in ovarian cancer tissues and adjacent normal tissues obtained from 152 subjects. A dual-luciferase reporter gene assay was performed to verify the relationship between miR-203a-3p and ATM. Human ovarian cancer cell lines (A2780 and SKOV3) were used to generate the Blank, miR-NC, miR-203a-3p mimic, Control siRNA, ATM siRNA, and miR-203a-3p inhibitor + ATM siRNA groups. The biological behaviors of ovarian cancer cells were evaluated by CCK-8, wound healing, and Transwell invasion assays, annexin V-FITC/PI staining and flow cytometry. The levels of Akt/GSK-3β/Snail pathway-related proteins were assessed by Western blotting.

Results: Ovarian cancer tissues showed lower miR-203a-3p levels and higher ATM levels than adjacent normal tissues, both of which were associated with the FIGO stage, grade and prognosis of ovarian cancer. As confirmed by a dual-luciferase reporter gene assay, miR-203a-3p could target ATM. Furthermore, the miR-203a-3p mimic had multiple effects, including the inhibition of the proliferation, invasion and migration of A2780 and SKOV3 cells, the promotion of cell apoptosis, the arrest of the cell cycle at the G1 phase, and the blockage of the Akt/GSK-3β/Snail signaling pathway. ATM siRNA had similar effects on the biological behaviors of ovarian cancer cells, and these effects could be reversed by a miR-203a-3p inhibitor.

Conclusion: miR-203a-3p was capable of hindering proliferation, migration, and invasion and facilitating the apoptosis of ovarian cancer cells through its modulation of the Akt/GSK-3β/Snail signaling pathway by targeting ATM, and therefore it could serve as a potential therapeutic option for ovarian cancer.

Keywords: Ovarian cancer, miR-203a-3p, ATM, Akt/GSK-3β/snail

Introduction

Worldwide, ovarian cancer is an extremely lethal cancer of the female reproductive system, and there are currently limited therapeutic options for its treatment [1]. Of all primary ovarian tumors, approximately 90% are epithelial ovarian cancer, which can be classified pathologically into different types, such as serous, mucinous, endometrioid, clear-cell and transitional-cell carcinomas [2]. In recent years, nearly 70% of patients have been diagnosed with ovarian cancer when they are in the middle or advanced stage due to the lack of effective screening strategies [3], resulting in a relatively low 5-year survival rate [4]. Given the above, a thorough understanding of the mechanism of ovarian cancer would be beneficial for the early diagnosis and clinical treatment of ovarian cancer.

MicroRNAs (miRNA) are noncoding RNAs derived from endogenous chromosomes that consist of approximately 22
nucleotides [5]. Recently, there has been wide agreement that a variety of miRNAs are expressed in an abnormal fashion and function as oncogenes or tumor suppressor genes in ovarian cancer and are therefore potential targets for the diagnosis and treatment of tumors [6, 7]. MiR-203a is located in the human chromosome region 14q32, which is an unstable region that contains approximately 12% of all discovered microRNA genes [8, 9]. A recent study reported that miR-203a-3p was poorly expressed in multiple myeloma [10], gastric cancer [8], bladder cancer [11], but that it was highly expressed in breast cancer [12], hepatocellular carcinoma [13], and nasopharyngeal carcinoma [14]. However, the expression of miR-203a-3p in ovarian cancer remains to be elucidated, and its mechanism also needs to be clarified. To the best of our knowledge, miRNA could play a role based on its sequence complementarities with the sequences of the 3’ UTRs in mRNAs from target genes, and the complementary pairing of specific bases causes the degradation or inhibits the translation of target mRNA, thereby regulating gene expression at the posttranscriptional level [15]. Notably, miR-203a-3p was shown to have regulatory effects in oral squamous cell carcinoma (OSCC) and glioma via targeting ATM [16, 17], which is a serine/threonine protein kinase located in chromosome region 11q22–23 [18]. In actuality, the abnormal expression of the ATM gene has strong implications for the clinical diagnosis of ovarian cancer, and the overexpression of ATM has been discovered to be closely associated with poor prognosis in ovarian cancer patients [19]. More importantly, ATM has been revealed to mediate the Akt/GSK-3β/Snail signaling pathway to influence the metastasis of ovarian cancer [20]. Nevertheless, it is still unknown whether miR-203a-3p can target the ATM-mediated Akt/GSK-3β/Snail pathway to affect the onset and development of ovarian cancer. Therefore, we detected the expression of miR-203a-3p and ATM in ovarian cancer tissues and adjacent normal tissues from clinical patients and then analyzed their correlations with the clinicopathological characteristics and prognosis in those patients. The A2780 cell line was selected for the in vitro experiments to determine whether and how miR-203a-3p can influence the biological characteristics of ovarian cancer cells through the modulation of the ATM-mediated Akt/GSK-3β/Snail pathway.

Materials and methods
Ethics statement
All patients in this study signed an informed consent form prior to the study, and all experiments gained the approval of the Ethics Committee for Clinical Experiments at Linyi Central Hospital.

Study subjects
From January 2011 to January 2013, 152 ovarian cancer patients were recruited into this study after pathological diagnosis, and ovarian cancer tissues and adjacent normal tissues were collected from them for subsequent experiments. The age of patients was 55.84 ± 16.04 years (median = 55 years). There were 51 cases at stage I-IIA and 101 cases at stage IIB-IV according to the FIGO staging system [21], and there were 26 cases at G1, 58 cases at G2, and 68 cases at G3 based on the tumor differentiation grade [22]. None of the patients underwent radiotherapy, hormone therapy, or other therapies and were prepared for surgery after complete examinations up on admission. The selected tissues were preserved in a cryopreservation tube and stored in a liquid nitrogen tank for later experiments.

qRT-PCR
Total RNA was extracted by TRIzol reagent, and the RNA concentration and purity was determined with a NanoDrop2000 (Thermo, Waltham, MA, USA), after which the RNA was preserved at -80°C. The primers were designed by using Primer 5.0 according to sequences published in the GenBank database and synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). The ABI PRISM 7500 Real-Time PCR system (ABI, USA) and SYBR Green I Fluorescent Kit (DRR041A, Takara) were used to perform PCR. Using U6/GAPDH as internal reference genes, the relative expression of the target genes was calculated using the 2^−△△Ct method. Independent experiments were conducted three times.

Immunohistochemical (IHC) staining
The paraffin-embedded tissue sections were deparaffinized, cultured in 3%H2O2 at room temperature for 10 min, and washed carefully with distilled water before soaking in PBS buffer 2 times for 5 min each. Then, the tissue sections were blocked in 10% normal goat serum diluted in PBS for an appropriate duration and incubated at room temperature for 30 min. Then, the primary antibodies were added overnight and incubated at 4°C, followed by washing with PBS buffer 3 times for 5 min each. Subsequently, these secondary antibodies were added for 2 h of incubation at 37°C, followed by washing with PBS buffer 3 times for 5 min each and development with DAB. The tissue sections were then rinsed with tap water, lightly counterstained with hematoxylin, and subjected to dehydration, hyalinization and section mounting. The sections were observed and photographed under a microscope. Two pathologists independently scored the IHC staining in a double-blind manner on the basis of the staining intensity and the number of positive cells. The staining intensity was scored as 0, 1, 2 or 3 to indicate absent, weak, moderate or strong staining, respectively, and the percentage of positive cells was graded as 0, 1, 2, 3, 4 or 5 indicate 0%, 1–5%, 5–25%, 25–50%, 50–
75% or 75–100% staining, respectively. The two scores were multiplied to evaluate the staining results.

**Dual-luciferase reporter gene assay**
The human ATM 3′-UTR fragment containing the binding site of miR-203a-3p in the 3′-UTR region was amplified and inserted into the TopMIR-Report vector to construct the wild-type plasmid ATM-WT and the mutant plasmid ATM-Mut. The combinations used for co-transfection were as follows: miR-NC/miR-203a-3p mimic/miR-203a-3p inhibitor + ATM-WT and miR-NC/miR-203a-3p mimic/miR-203a-3p inhibitor + ATM-Mut. The transfection of the human ovarian cancer cell lines (A2780 and SKOV3) was conducted in accordance with the instructions included with the Lipofectamine 2000 kit (11668–027, Invitrogen, Carlsbad, CA, USA). The luciferase activity of the cells was determined by a dual-luciferase reporter gene assay (Promega, Madison, WI, USA).

**Cell groupings**
Human ovarian cancer cell lines (A2780 and SKOV3) were obtained from the Cell Bank of the Chinese Academy of Sciences and cultured in DMEM supplemented with 10% fetal bovine serum and 100 units/ml penicillin-streptomycin in an incubator at 37 °C in 5% CO₂. When cells covered 80% of the visual field under amicroscope, they were digested with 0.25% trypsin and passaged. Then, the cells were divided and assigned to the Blank, miR-NC, miR-203a-3p mimic, Control siRNA, ATM siRNA, and miR-203a-3p inhibitor + ATM siRNA groups. In this study, the miR-203a-3p inhibitor (Catalog #: 4464084), the miR-203a-3p mimic (Catalog #: 4464066) and the miRNA mimic negative control (Catalog #:4464058) were purchased from Fisher Scientific (Ottawa, Ontario, Canada). The control siRNA (Catalog #5sc-37,007) and ATM siRNA (Catalog #sc-29,761) were provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA).

**Western blot analysis**
The proteins were extracted with a BCA kit (Pierce, Rockford, IL, USA), and their concentration was determined. Then, loading buffer was added to the extracted proteins and heated for 10 min at 95 °C. Electrophoresis was used for the separation of the proteins in a 10% polyacrylamide gel with a voltage of 80 V for concentration and 120 V for separation. A wet transfer was used to transfer the proteins to a polyvinylidene fluoride (PVDF) membrane, which was placed in 5% BSA at room temperature for 1 h for blocking, followed by incubation with the primary antibodies overnight at 4 °C. Next, the membrane was washed with TBST 3 times for 5 min each. Later, the secondary antibodies were added and incubated for another 1 h, and the membrane was rinsed again with TBST 3 times for 5 min each. Finally, chemiluminescent detection was used for development. The ratio of the gray value of the target band to that of the reference band was used to measure the relative expression level of the proteins, and GAPDH was used as the loading control. Image J software was used for the gray value analysis, and the experiment was repeated three times.

**CCK-8 assay**
Cells collected at the logarithmic growth phase were digested with 0.25% trypsin, and the cell suspension was inoculated into 96-well plates at10⁴ cells/well (100 µl). The wells on the margin area were filled with sterile PBS, and the cells were incubated accordingly. When the cell confluence reached 80%, the cells were divided into groups as described above before culture for 12 h, 24 h, 36 h, 48 h and 72 h. Next, 10 µl CCK solution was added to each well, and cells were cultured at 37 °C for 4 h in an incubator with 5%CO₂. The optical density (OD) value was determined with a microplate reader at a wavelength of 450 nm.

**Wound healing assay**
Once cells had adhered to the wall and covered the bottom of the plate, a sterilized pipette tip was used to draw a line across the plate at the time recorded as 0 h. It is important to ensure a consistent width for each scratch and to mark the cover of the 6-well plate, which was photographed to facilitate the relocation of the same visual field. After incubation at37°C for 24 h, the culture medium was removed, and the plate was washed with PBS buffer three times. The cell debris produced during scratching was washed away, followed by the addition of serum-free culture medium and imaging at 24 h. The images were obtained with an Olympus inverted microscope (CKX31, Japan), and the experiment was repeated independently three times.

**Transwell invasion assay**
Matrigel was melted and added into a Transwell chamber. Cell plates containing Transwell chambers were incubated at37°C for 30 min. Preheated media was added to the cell culture plate, which was placed in an incubator for 2 h of hydration at 37°C. Next, the liquid in the upper and lower chambers was carefully removed, and 0.5 ml cell suspension at a density of 5 × 10⁴ cells/ml was added into each Transwell chamber for 24 h of incubation at37°C. Then, each chamber was removed to wipe away cells on the upper side, which was then washed with PBS buffer three times and soaked in precooled methanol for 30 min. The cells that had migrated into the lower chamber were fixed and incubated in 1% crystal violet solution for 10 min for staining. Running water
was used to wash away the crystal violet solution, and the chamber was removed for drying. The cells were stained for 10 min and washed with flowing water. After thorough rinsing, the cells were removed for drying. An Olympus inverted microscope was used to observe and photograph the cells that had migrated into the lower chamber of the Transwell system. A statistical analysis was carried out, and the experiment was repeated three times independently.

**Annexin V-FITC/PI staining**

First, the cell culture medium in a 6-well plate was removed, placed in a centrifuge tube, washed with PBS buffer, and digested with 0.25% trypsin. Next, a single cell suspension (1 × 10^6 cells/ml) was generated by replacing the digestion solution, followed by 5 min of centrifugation at 12000 rpm at 4 ºC. Then, 100 µl of cell suspension allowed to warm to room temperature, mixed with propidium iodide (PI, 10 mg/ml) and RNase A (10 mg/ml), and incubated for 30 min at 4 ºC. The suspension was detected by a flow cytometer (BD Biosciences, San Diego, CA, USA) immediately after the addition of 400 µl staining buffer, and Cell Quest software was used for the data analysis. The experiment was repeated at least three times independently.

**Flow cytometry**

Approximately 48 h after transfection, the cells were collected, digested with 0.25% trypsin, and adjusted to a density of 1 × 10^6 cells/mL. Then, the cell suspension (1 mL) was centrifuged at 1500 rpm for 10 min, and the supernatant was discarded, followed by the addition of 2 mL PBS for each milliliter of cells. After centrifugation, the supernatant was discarded, and precooled 70% ethanol was used to fix cells overnight at 4 ºC. The next day, the cells were washed twice with PBS buffer, 100 µl of cell suspension was removed, and 50 µg of RNase-containing PI solution was added and incubated for 30 min in the dark. Finally, the cells were filtered with a 100-mesh nylon mesh, and a cell cycle analysis was performed with a flow cytometer (BD Biosciences, San Diego, CA, USA).

**Statistical analysis**

The measurement data are presented as the mean ± standard deviation (SD) and were analyzed using the statistical software SPSS21.0 (SPSS Inc. Chicago, IL, USA). One-way ANOVA was used for comparisons among multiple groups followed by Tukey’s multiple comparison test. The expression of miR-203a-3p and ATM in ovarian cancer tissues and adjacent normal tissues was analyzed by a paired-sample t-test, and their correlations with the clinicopathological characteristics of patients was tested by Student’s t-test or a nonparametric rank sum test. The correlation of miR-203a-3p expression with ATM expression was verified using Pearson’s correlation analysis, and survival curves from the different groups were compared using the Kaplan-Meier method and the log-rank test. A Cox proportional hazards model was constructed to estimate the prognostic factors that influenced quality of life in ovarian cancer patients. Statistical significance was indicated when P < 0.05.

**Results**

**Expression of miR-203a-3p and ATM in ovarian cancer tissues and adjacent normal tissues**

According to the results, ovarian cancer tissues exhibited reduced miR-203a-3p expression and increased ATM expression compared to adjacent normal tissues (both P < 0.05, Fig. 1a). The correlation analysis showed a negative correlation for miR-203a-3p expression and ATM expression (r = −0.698, P < 0.001, Fig. 1b). Western blotting was performed, which found the same expression trend for ATM protein expression as was observed for ATM mRNA expression (Fig. 1c–d). When we evaluated the positive ATM expression with immunohistochemical staining, we observed that the positive ATM expression rate was higher in ovarian cancer tissues (58.55%, 89/152) than in adjacent normal tissues (13.82%, 21/152) (P < 0.05, Fig. 1e–f).

**Association of miR-203a-3p and ATM expression with the clinicopathological features of ovarian cancer**

The expression of miR-203a-3p and ATM in ovarian cancer tissues was not significantly different based on age or histology (all P > 0.05) but was closely associated with the FIGO stage and tumor grade in ovarian cancer patients (all P < 0.05). The higher the FIGO stage was and the less differentiation was found in the tumor, the lower the miR-203a-3p level would be and the higher the ATM level would be (Table 1).

**Effect of miR-203a-3p and ATM expression on the prognosis of ovarian cancer**

Kaplan-Meier survival analysis demonstrated that the prognosis of ovarian cancer patients was closely related to FIGO stage and grade but not to age and histology (Fig. 2). In addition, patients with high miR-203a-3p expression (≥0.390) had longer survival times than those with low miR-203a-3p expression (<0.390), and the mean survival times were 48.77 ± 1.85 months and 37.99 ± 2.10 months, respectively (χ² = 12.690, P = 3.68E-4), for patients with high and low miR-203a-3p expression. In addition, the survival time of patients with low ATM expression (≥3.721) was longer than that of patients with low ATM expression (<3.721) (50.36 ± 1.60 months vs. 36.54 ± 2.18 months, respectively, χ² = 19.520, P = 9.95E-6). Multivariate Cox regression
Fig. 1 Expression of miR-203a-3p and ATM in ovarian cancer tissues and adjacent normal tissues. Note: a The expression levels of miR-203a-3p and ATM in ovarian cancer tissues and adjacent normal tissues detected by qRT-PCR; b The correlation between miR-203a-3p expression and ATM expression in ovarian cancer tissues; c-d ATM protein expression levels in ovarian cancer tissues and adjacent normal tissues examined by Western blot; e-f, Positive ATM expression in ovarian cancer tissues and adjacent normal tissues detected by immunohistochemical staining.

Table 1 Association of miR-203a-3p and ATM with clinicopathological features of ovarian cancer patients

| Characteristics     | N   | miR-203a-3p | P      | ATM  | P      |
|---------------------|-----|-------------|--------|------|--------|
| Age (years)         |     |             |        |      |        |
| ≤ 55                | 75  | 0.39 ± 0.03 | 3.73 ± 0.31 | 0.39 ± 0.03 | 3.67 ± 0.31 | 0.227 |
| > 55                | 77  | 0.39 ± 0.03 | 0.528  | 3.67 ± 0.31 | 0.227 |
| FIGO stage          |     |             |        |      |        |
| Early (I-IIA)       | 51  | 0.41 ± 0.02 | 3.58 ± 0.29 | 5.14E-13 | 3.76 ± 0.30 | 0.001 |
| Advanced (IIB-IV)   | 101 | 0.38 ± 0.02 | 5.14E-13 | 3.76 ± 0.30 | 0.001 |
| Histology           |     |             |        |      |        |
| serous              | 76  | 0.39 ± 0.02 | 3.70 ± 0.28 | 3.70 ± 0.34 | 0.970 |
| non-serous          | 76  | 0.39 ± 0.03 | 0.740  | 3.70 ± 0.34 | 0.970 |
| Grade               |     |             |        |      |        |
| 1                   | 26  | 0.43 ± 0.02 | 3.32 ± 0.22 | 3.32 ± 0.22 | 0.227 |
| 2                   | 58  | 0.40 ± 0.01* | 3.72 ± 0.21* | 3.72 ± 0.21* | 0.227 |
| 3                   | 68  | 0.37 ± 0.02* | 1.80E-39 | 3.83 ± 0.29* | 2.08E-14 |

Note: *, P < 0.05 compared with Grade 1; #, P < 0.05 compared with Grade 2
analysis showed that ATM expression was an independent risk factor for the prognosis of ovarian cancer (HR: 2.579, 95%CI: 1.581~4.207, *P* = 1.49E-04, Table 2).

**MiR-203a-3p could target ATM**

Based on the information generated by the bioinformatics analysis tools miRDB (http://mirdb.org/cgi-bin/target_detail.cgi?targetID=3441169) and microRNA.org (http://www.microrna.org/microrna/getMrna.do?gene=472&utr=14588 &organism=9606#hd), ATM was a downstream target gene of miR-203a-3p (Fig. 3a-b). As confirmed by the dual-luciferase reporter gene assay, within the ATM-WT groups, the miR-203a-3p mimic group showed decreased luciferase activity, and the miR-203a-3p inhibitor group demonstrated increased luciferase activity in comparison with the miR-NC group (all *P* < 0.05). Nevertheless, no significant difference was observed in luciferase activity among the ATM-Mut groups (all *P* > 0.05, Fig. 3c).

### Table 2

Univariate and multivariate Cox regression models to analyze the prognostic factors of ovarian cancer patients

| Characteristics              | Univariate analysis | Multivariate analysis |
|------------------------------|---------------------|-----------------------|
|                              | HR                  | 95%CI                 | *P* |
| Age                          |                     |                       |     |
| > 55 vs. ≤ 55                | 0.877               | 0.568~1.354           | 0.555 |
| Histology                    | 0.753               | 0.469~1.212           | 0.489 |
| Grade                        |                     |                       |     |
| G2 vs. G1                    | 1.762               | 0.803~3.867           | 0.158 |
| G3 vs. G1                    | 3.428               | 1.614~7.280           | 0.001 |
| miR-203a-3p expression       |                     |                       |     |
| Low vs. High                 | 2.189               | 1.401~3.419           | 0.001 |
| ATM expression               |                     |                       |     |
| High vs. Low                 | 2.655               | 1.685~4.183           | 2.55E-05 |

Fig. 2 The prognostic analysis of 152 ovarian cancer patients. Note: a Age; b Histology; c FIGO stage; d Grade; e miR-203a-3p; f ATM expression.
Comparison of miR-203a-3p and ATM expression in ovarian cancer cells
As shown in Fig. 4, the miR-203a-3p mimic group had increased miR-203a-3p and decreased ATM, while the miR-203a-3p inhibitor + ATM siRNA group exhibited decreased miR-203a-3p compared with the miR-NC group (all \( P < 0.05 \)). When compared to the control siRNA group, the ATM siRNA group presented reduced ATM (\( P < 0.05 \)), but no observable difference was found in miR-203a-3p expression (\( P > 0.05 \)). However, there was no significant change in ATM expression among the miR-NC, Control siRNA, and miR-203a-3p inhibitor + ATM siRNA groups (all \( P > 0.05 \)).

Effects of miR-203a-3p on proliferation, apoptosis and the cell cycle in ovarian cancer cells via its targeting of ATM
Compared with that observed in the miR-NC group and the Control siRNA group, the miR-203a-3p mimic and the ATM siRNA reduced the proliferation and promoted the apoptosis of A2780 and SKOV3 cells (all \( P < 0.05 \)). However, there was no obvious difference among the Blank group, miR-NC group, Control siRNA group, and miR-203a-3p inhibitor + ATM siRNA group in terms of the proliferation and apoptosis rate of cells (all \( P > 0.05 \), Fig. 5). Furthermore, the numbers of G1 phase cells were significantly increased in the miR-203a-3p mimic group and the number of S phase cells was remarkably decreased in the ATM siRNA group (all \( P < 0.05 \)). When compared with the ATM siRNA group, the number of G1 phase cells declined and the number of S phase cells increased in the miR-203a-3p inhibitor + ATM siRNA group (all \( P < 0.05 \), Fig. 6).

Effect of the targeting of ATM by miR-203a-3p on the migration and invasion of ovarian cancer cells
According to the results of the wound healing assay and the Transwell invasion assay (Fig. 7), the cells in the miR-NC group showed no significant changes in terms of migration distance or invasive cell numbers compared with those in the Blank group (both \( P > 0.05 \), while
those in the miR-203a-3p mimic group and the si-ATM group showed increased migration distances and decreased invasive cell numbers (all \( P < 0.05 \)). However, when compared with those in the miR-203a-3p inhibitor group, the cells in the miR-203a-3p inhibitor + ATM siRNA group showed clear reductions in cell migration and invasion (both \( P < 0.05 \)).

**Effect of the targeting of ATM by miR-203a-3p on the Akt/GSK-3β/snail signaling pathway**

Compared with the Blank group, the miR-NC group and Akt/GSK-3β/Snail group showed no significant differences in the expression of Akt/GSK-3β/Snail pathway-related proteins (all \( P > 0.05 \)). After cells were transfected with the miR-203a-3p mimic or ATM siRNA, the expression levels of p-AKT, p-GSK-3β and Snail were all remarkably decreased (all \( P < 0.05 \)). In addition, when compared to the ATM siRNA group, the miR-203a-3p inhibitor + ATM siRNA group exhibited upregulated expression of p-AKT, p-GSK-3β and Snail (all \( P < 0.05 \), Fig. 8).

**Discussion**

MiR-203, as the first keratinocyte-specific miRNA that was discovered [23], was proven in a recent study to exert a significant influence on the occurrence and progression of bladder cancer [24], and its epigenetic silencing was also observed in hematopoietic malignancies [9]. To date, accumulating evidence has revealed that miR-203 can effectively regulate chemotherapeutic resistance to cisplatin [25], cell invasiveness [26], cell proliferation [27] and metastasis [28], which could also allow it to function as a biomarker to predict prognosis in certain diseases [29].

An important finding of this study was that miR-203a-3p expression in ovarian cancer tissues was lower than that in adjacent normal tissues, and it had an important effect on the FIGO stage, tumor grade and prognosis of patients. A similar study by Liu Y et al. also revealed that the downregulation of miR-203a was closely correlated to the TNM stage, the degree of pathological differentiation and lymph node metastasis in esophageal squamous cell carcinoma (ESCC) [30]. In addition, miR-203a deletion indicated a poor prognosis for both hepatocellular carcinoma (HCC) and gastric cardia adenocarcinoma (GCA) patients [31, 32]. As previously reported, the promoter region of miR-203a contains a CPG island that is 875 bp in length [33] and is located in the proximal promoter region [30]. In addition, the methylation of miR-203a has been found to be tumor-specific, since miR-203a methylation was only observed in cancer cells but not in normal cells [9]. The hypermethylation of miR-203a can promote the proliferation of chronic myelogenous leukemia (CML) cells by inhibiting the carcinogenic BCR-ABL fusion protein, suggesting that miR-203a hypermethylation is carcinogenic in CML [34]. It has been proven that hypermethylation of the proximal promoter of miR-203a can affect its transcriptional activity [30], and the methylation rate of Cpg islands in miR-203 was significantly negatively correlated with the expression of miR-203 [32, 35]. In one particular instance, the hypermethylation of miR-203a was apparently associated with the invasion and metastasis of
ovarian cancer, as suggested by LoginovVI et al. [36]. However, we did not detect the methylation of miR-203a-3p in ovarian cancer tissues in this study due to limitations in time and funding, but this will be explored in future experiments. Currently, accumulating evidence also highlights the protective role of the overexpression of miR-203a in various tumors. For instance, in bladder cancer, the overexpression of miR-203a contributed to increases in cell proliferation, invasion, and migration, the inhibition of EMT, the arrest of the cell cycle, and an increase in apoptosis in cells [11]. Similarly, the findings of our study also demonstrated that the miR-203a-3p mimic could effectively inhibit ovarian cancer cell proliferation, invasion, and migration, accelerate cell apoptosis, and cause cell cycle arrest at the G1 phase, which further confirmed the anti-oncogenic function of miR-203a-3p in ovarian cancer.

ATM is a protein consisting of 3056 amino acids that has a molecular weight of 350 kDa [37]. Its activation not only has an important effect on responses to DNA double-strand breakages in cells but also shows a close association with the occurrence and development of tumors. For example, the mRNA and protein levels of ATM were found to be dramatically higher in nasopharyngeal carcinoma tissues than in adjacent normal tissues [38]. In addition, the upregulation of ATM may be a major cause of therapeutic resistance in ovarian cancer [19]. In our study, high ATM expression was correlated
with clinicopathological features and poor prognosis of ovarian cancer patients, whereas the inhibition of ATM expression is expected to become a potential therapy for patients with ovarian cancer. Another study reported that the ATM inhibitor KU-55933 can hinder cancer cell proliferation by inducing G1 blockade and thereby triggering apoptosis in cancer cells [39]. Liu Ret al. also revealed that ATM deletion could dramatically decrease the proliferation, migration and invasion of colon cancer cells [40], which could also lead to a remarkable reduction in migration and epithelial-mesenchymal transition (EMT) in prostate cancer cells [41]. In our experiment, ATM was confirmed to be the downstream target gene of miR-203a-3p through bioinformatics prediction and a dual-luciferase reporter gene assay. At the same time, we did find a negative relationship between ATM and miR-203a-3p in our clinical investigation, and the higher expression of ATM predicted a poor prognosis in ovarian cancer patients according to a univariate Cox regression model, highlighting the possible protective role of ATM. However, the results of the multivariate analysis showed that ATM was associated with prognosis, while miR-203a-3p was not associated with prognosis. The
possible reason for this finding might be the small sample size used in this study, the limited clinical features, and the activity of other potential regulators of ATM or targets of miR-203a-3p. Notably, activated ATM can cause the binding of HSP90 to HER2 and then block the ubiquitination and degradation of HER2 to maintain its stability, and it can eventually regulate its downstream Akt activity to affect the malignancy of breast cancer.

Fig. 7 Effect of miR-203a-3p on the migration and invasion of A2780 cells (a-c) and SKOV3 cells (d-e) by targeting ATM. Note: The same letters indicate nonsignificant differences, \( P > 0.05 \), and the different letters indicate statistically significant differences, \( P < 0.05 \).

Fig. 8 Effect of miR-203a-3p on Akt/GSK-3\( \beta \)/Snail signaling pathway via its targeting of ATM in A2780 cells (a-b) and SKOV3 cells (c-d). Note: The same letters indicate nonsignificant differences, \( P > 0.05 \), and the different letters indicate statistically significant differences, \( P < 0.05 \).
cells [42]. Moreover, in malignant glioma cells, the ATM-Akt signaling pathway could mediate cell migration, as discovered by Golding et al. [43]. There was also evidence that a specific inhibitor of ATM (KU55933) could effectively inhibit cell migration induced by sorafenib, a chemotherapeutic agent, in HCC cells [44]. On the other hand, GSK-3β, which is a downstream gene in the AKT signaling pathway, can lead to the phosphorylation of the Snail transcription factor, thus regulating EMT and participating in tumor invasiveness and metastasis [45–47]. Additionally, Mianen and colleagues also demonstrated that ATM was highly activated in breast cancer tissues with advanced lymph node metastasis, and ATM was associated with the positive expression of Snail, which is an EMT-related molecule [48]. Their in vitro experiments confirmed that activated ATM could phosphorylate Snail and lead HSP90 to bind to Snail to maintain its stability, thereby promoting EMT transformation and lymph node metastasis. Through Western blot analysis, we found that the expression levels of p-AKT, p-GSK-3β and Snail were all decreased dramatically after transfection with the miR-203a-3p mimic or ATM siRNA. However, those cells that were cotransfected with the miR-203a-3p inhibitor and ATM siRNA showed no significant differences when compared to nontransfected cells in terms of those indicators, suggesting that miR-203a-3p can target ATM to mediate the Akt/GSK-3β/Snail signaling pathway in ovarian cancer.

Conclusion

In conclusion, miR-203a-3p was downregulated and ATM was upregulated in ovarian cancer tissues. In addition, because the biological behaviors of ovarian cancer cells can be modulated by miR-203a-3p through its effects on the Akt/GSK-3β/Snail signaling pathway via ATM, miR-203a-3p upregulation is expected to provide a beneficial strategy for the clinical treatment of ovarian cancer.

Acknowledgments

We thank all the reviewers for their helpful suggestions and comments about our study.

Authors’ contributions

HYL and YYZ conceived and designed the study. BLZ performed the experiments. FZF interpreted the data and corrected the manuscript. HTZ wrote the manuscript. HY corrected the manuscript and critically revised the manuscript. BZ participated in the revision of the manuscript. All authors approved the final manuscript.

Funding

None.

Availability of data and materials

All data generated and analyzed during this work were included in this article.

Ethics approval and consent to participate

All the patients in this study signed the informed consent form prior to the study, and all experiments gained the approval of the Ethics Committee for Clinical Experiments at Linyi Central Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Obstetrics and Gynecology, Linyi Central Hospital, Linyi 276400, Shandong, China. 2Department of Infectious, Linyi Central Hospital, Linyi 276400, Shandong, China. 3Department of Rehabilitation Medicine, Linyi Central Hospital, No 17, Jianguang Road, Linyi 276400, Shandong, China.

Received: 6 January 2019 Accepted: 12 June 2019 Published online: 05 July 2019

References

1. Agostini A, Panagopoulos I, Davidson B, Trope CG, Heim S, Micci F. A novel truncated form of HMG2A2 in tumors of the ovaries. Oncol Lett. 2016;12:1559–63.
2. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–49.
3. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW. Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer. 2004;91:275–31.
4. Teng Z, Han R, Huang X, Zhou J, Yang J, Luo P, Wu M. Increase of incidence and mortality of ovarian Cancer during 2003–2012 in Jiangsu Province, China. Front Public Health. 2016;4:146.
5. Wilson KD, Hu S, Venkatasubrahmamyan S, Fu JD, Sun N, Abijal OE, Baugh JJ, Jia F, Ghosh Z, Li RA, Butte AJ, Wu JC. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet. 2010;3:426–35.
6. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013;8:e77853.
7. Nagaraj AB, Joseph P, Difeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015;9:241–57.
8. Wang Z, Zhao Z, Yang Y, Luo M, Zhang M, Wang X, Liu L, Hou N, Guo Q, Song T, Huang B, Huang C. MiR-99b-5p and miR-203a-3p function as tumor suppressors by targeting IGF-IR in gastric Cancer. Sci Rep. 2018;8:10119.
9. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496–506.
10. Yang M, Zhang L, Wang X, Zhou Y, Wu S. Down-regulation of miR-203a by IncRNA PVT1 in multiple myeloma promotes cell proliferation. Arch Med Sci. 2018;14:1333–9.
11. Na XY, Shang XS, Zhao Y, Ren PP, Hu XQ. MiR-203a functions as a tumor suppressor in bladder cancer by targeting SIX4. Neoplasma. 2016;63:211–21.
12. Gomes BC, Martins M, Lopes P, Moruajo I, Oliveira M, Araujo A, Ruffe J, Rodrigues AS. Prognostic value of microRNA-203a expression in breast cancer. Oncol Rep. 2016;36:1748–56.
13. Huo W, Du M, Pan X, Zhu H, Gao Y, Li Z. MiR-203a-3p1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open Bio. 2017;7:1085–91.
14. Jiang Q, Zhou Y, Yang H, Li L, Deng X, Cheng C, Xie Y, Luo X, Fang W, Liu Z. A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma. Oncotarget. 2016;7:3088–91.
15. Pei Y, Wang X, Zhang X. Predicting the fate of microRNA target genes based on sequence features. J Theor Biol. 2009;261:17–22.
16. Shieh TM, Huang YT, Yu CC, Hsia SM, Shih YH, Wang TH. P0028. Isoliquiriigenin causes DNA damage and inhibits ATM expression in oral squamous cell carcinoma. Eur J Cancer. 2015;51:8–9.
17. Yang CH, Wang Y, Sims M, Cai C, He P, Hacker H, Yue J, Cheng J, Boop FA, Pfeffer LM. MicroRNA203a suppresses glioma tumorigenesis through an ATM-dependent interferon response pathway. Oncotarget. 2017;8:12980–91.

18. Filipp AR, Franco P, Galliano M, Ricardi U. Peripheral blood complete remission after splenic radiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiat Oncol. 2006;1:55.

19. Abdel-Fattah TM, Arora A, Mosesley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin. 2014;210–7.

20. Yin S, Wang P, Yang L, Liu Y, Wang Y, Liu M, Qi Z, Meng J, Shi TY, Yang G, Zang R. Wip1 suppresses ovarian cancer metastasis through the ATM/AKT/submitmediated signaling. Oncotarget. 2016;7:29599–70.

21. Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290:839–42.

22. Chen T, Xu C, Chen J, Ding C, Xu Z, Liu C, Zou J. MicroRNA-203 inhibits cell proliferation and invasion by targeting BTM1 in non-small cell lung cancer. Oncol Lett. 2015;9:2639–46.

23. Haller A, Grunewald TG, Orth M, Reiss C, Kneitz B, Spahn M, Butt E. Loss of ATM inactivation promotes breast cancer growth and metastasis. Cancer Biol Ther. 2016;17:5387–92.

24. Ru P, Steele R, Hsieh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast Cancer cells and enhances cisplatin Chemosensitivity. Genes Cancer. 2011;2:70–7.

25. Chen T, Xu C, Chen J, Ding C, Xu Z, Liu C, Zou J. MicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancer. Oncol Lett. 2015;9:2639–46.

26. GOLDING SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoureau L, Menear KA, OConnor MJ, Povirk LF, van Meter T, Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8:2894–902.

27. Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggi G, Falcioni R, Gacciari D, Di Carlo S, Sperioli F, Ciccioni MT, Barla D. ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat Commun. 2015;6:8686.

28. Ru P, Steele R, Hsieh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast Cancer cells and enhances cisplatin Chemosensitivity. Genes Cancer. 2011;2:70–7.

29. Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saiga...